Last 23 quarters of trend data · Healthcare · Medical - Care Facilities
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.07 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.56 | 6.23 | 3.99 | 0.21 | 0.06 | 0.06 | 0.09 | 0.31 | 0.44 | 0.31 | 0.13 | 0.16 | 0.49 |
| — | +9979.7% | +4472.4% | -32.1% | -86.7% | -80.3% | -31.4% | +89.6% | -11.6% | -77.9% | -91.6% | -93.4% | -84.8% | |
| P/B Ratio | 60.43 | — | — | 17.34 | 6.51 | 1.59 | 1.18 | 2.84 | 2.63 | 1.43 | 0.48 | 0.51 | 1.13 |
| — | — | — | +510.5% | +147.8% | +11.4% | +144.6% | +461.3% | +132.0% | -50.3% | -83.8% | -87.7% | -82.7% | |
| P/FCF | — | — | — | — | 2.40 | 5.06 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
The Oncology Institute, Inc.'s operating margin was -5.9% in Q3 2025, up 3.5 pp QoQ and up 8.0 pp YoY. This marks the 7th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -9.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 3.7% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 13.7% | 13.9% | 14.6% | 16.5% | 14.6% | 14.4% | 13.2% | 12.6% | 16.8% | 19.5% | 18.8% | 18.5% | 21.9% |
| — | -3.7% | +10.6% | +30.7% | -12.9% | -26.2% | -29.9% | -31.7% | -23.4% | -2.6% | +3.0% | -17.2% | +37.3% | |
| Operating Margin | -15.3% | -5.9% | -9.4% | -9.5% | -11.9% | -13.9% | -16.6% | -19.0% | -17.8% | -17.0% | -18.6% | -43.1% | -35.1% |
| — | +57.5% | +43.6% | +50.0% | +33.2% | +18.3% | +10.8% | +56.0% | +49.2% | +45.1% | +38.0% | -28.8% | +55.0% | |
| Net Margin | -16.4% | -12.1% | -14.2% | -18.8% | -13.1% | -16.1% | -15.7% | -21.0% | -21.9% | -21.2% | -21.1% | -39.4% | -15.4% |
| — | +25.1% | +9.6% | +10.7% | +39.9% | +24.0% | +25.4% | +46.6% | -41.9% | -416.0% | -135.3% | -212.6% | +20.6% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -213.4% | — | — | -452.4% | -138.2% | -72.1% | -43.9% | -40.5% | -29.1% | -22.3% | -18.5% | -26.9% | -8.7% |
| — | — | — | -1018.3% | -375.0% | -224.1% | -137.9% | -50.4% | -234.0% | -948.1% | -333.1% | -264.7% | +34.9% | |
| ROA | -33.9% | -10.2% | -10.5% | -11.6% | -7.5% | -9.0% | -8.1% | -9.6% | -8.8% | -7.8% | -7.3% | -12.0% | -4.0% |
| — | -13.6% | -30.4% | -21.0% | +14.6% | -15.6% | -10.8% | +20.1% | -118.2% | -588.1% | -164.3% | -227.9% | +41.8% | |
| ROIC | -40.9% | -23.4% | -12.7% | -10.3% | -10.6% | -9.8% | -10.0% | -10.0% | -7.5% | -6.3% | -6.1% | -12.0% | -9.6% |
| — | -137.7% | -27.5% | -2.2% | -41.5% | -57.1% | -63.1% | +16.0% | +21.7% | +47.8% | +69.9% | +80.1% | +95.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 32.6% YoY to 1.68x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 34.31 | — | — | 20.18 | 34.31 | 7.94 | 4.37 | 2.90 | 2.10 | 1.63 | 1.37 | 1.12 | 0.87 |
| — | — | — | +595.5% | +1535.0% | +386.2% | +218.1% | +159.5% | +141.9% | +97.0% | +791.3% | +689.9% | +49282.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.15 | 1.68 | 1.62 | 1.79 | 2.15 | 2.49 | 3.31 | 3.08 | 4.12 | 4.71 | 3.11 | 3.95 | 4.37 |
| — | -32.6% | -51.1% | -41.8% | -47.8% | -47.2% | +6.6% | -22.0% | -5.6% | +7.8% | +0.0% | -10.9% | -15.4% | |
| Quick Ratio | 1.96 | 1.39 | 1.37 | 1.59 | 1.96 | 2.27 | 2.99 | 2.83 | 3.73 | 4.34 | 2.74 | 3.61 | 4.06 |
| — | -38.8% | -54.0% | -44.0% | -47.5% | -47.6% | +8.9% | -21.6% | -8.1% | +6.7% | -4.4% | -13.8% | -18.0% | |
| Interest Coverage | -8.02 | -4.19 | -6.00 | -1.78 | -10.21 | -6.23 | -7.73 | -9.05 | -7.88 | -5.17 | -5.59 | -12.40 | -10.24 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonThe Oncology Institute, Inc.'s current P/E is -4.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
The Oncology Institute, Inc.'s current operating margin is -15.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking The Oncology Institute, Inc.'s business trajectory between earnings reports.